Back to Search
Start Over
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs
- Source :
- International Journal of Molecular Sciences, International Journal of Molecular Sciences, Vol 20, Iss 7, p 1607 (2019)
- Publication Year :
- 2019
-
Abstract
- Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology, with objective responses registered in multiple cancer types. However, reliable predictive markers of tumor responsiveness are still lacking. These markers need to be urgently identified for a better selection of patients that can be candidates for immunotherapy. In this pilot study, a cohort of 34 consecutive patients bearing programmed death-ligand 1 (PD-L1)-positive non-small cell lung carcinoma (NSCLC), treated with pembrolizumab, was considered. The retrospective immuno-phenotypic analysis performed on the original tumor biopsies allowed for the identification of a specific “galectin signature”, which strongly correlated with tumor responsiveness to anti PD-1 immunotherapy. We observed that the large majority of patients (about 90%) with high galectin-3 tumor expression (score 3+) showed an early and dramatic progression of the disease after three cycles of treatments. In contrast, all patients with negative or low/intermediate expression of galectin-3 in tumor cells showed an early and durable objective response to pembrolizumab, indicating galectin-3 as an interesting predictive marker of tumor responsiveness. The galectin-3 signature, at least in NSCLCs, promises a better selection of patient candidates for immunotherapy, reducing unnecessary treatment exposures and social costs. A large multicenter study is ongoing to validate this finding.
- Subjects :
- Oncology
Lung Neoplasms
medicine.medical_treatment
Galectin 3
Cell
Programmed Cell Death 1 Receptor
Disease
Pembrolizumab
Checkpoint inhibitors
Galectin-3
Non-small cell lung carcinoma
Predictive marker
Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
Humans
Immunohistochemistry
Immunotherapy
Middle Aged
Retrospective Studies
lcsh:Chemistry
non-small cell lung carcinoma
Monoclonal
Non-Small-Cell Lung
lcsh:QH301-705.5
Humanized
Spectroscopy
Tumor
Communication
General Medicine
Blood Proteins
Computer Science Applications
Immunological
medicine.anatomical_structure
pembrolizumab
predictive marker
medicine.medical_specialty
Galectins
Antineoplastic Agents
Antibodies
Catalysis
Inorganic Chemistry
Internal medicine
galectin-3
medicine
Carcinoma
Physical and Theoretical Chemistry
Molecular Biology
Galectin
business.industry
Organic Chemistry
medicine.disease
lcsh:Biology (General)
lcsh:QD1-999
business
checkpoint inhibitors
Biomarkers
Subjects
Details
- ISSN :
- 14220067
- Volume :
- 20
- Issue :
- 7
- Database :
- OpenAIRE
- Journal :
- International journal of molecular sciences
- Accession number :
- edsair.doi.dedup.....00a9b9126b926ecc2db8767550de75c7